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ABSTRACT 
The aims of this study were to evaluate the impact of conjugate vaccine A, MenAfriVac, on Neisseria meningitidis (Nm) 
asymptomatic carriage and cerebrospinal meningitis in three health districts (Bogodogo, Kaya, and Dandé) of Burkina Faso. 
Asymptomatic carriage of Nm was assessed by performing cross-sectional studyrepeated (rounds 1 to 10) before and after 
introduction of the conjugate vaccine against serogroup A of N. meningitidis (NmA), MenAfriVac. In each round at least 
1,500 people were enrolled in each district for a month. Data oncases of meningococcal meningitis in the three studied 
health districts were collected through meningitides epidemiological surveillance of Burkina Faso.Nm was identified in680 
of 23,885 throat swabs before vaccination (2. 84%)withNmYasthe dominant serogroup(1.87%). During the same period (2009 
and 2010), 891 cases of suspected meningitis were reported in the three health districts among whom 42 were due toNm 
(4.71%) withNmX (3.70%) asthe most frequently identified serogroup. After vaccination, Nm was identified in 1117 of 27,245 
pharyngeal samples (6.42%); NmX (4.42%) wasthe dominantserogroup. From 2011 to 2013, 965 cases of suspected meningitis 
were reported in all health facilities in the three studied health districts located in the geographical study area; 91 was due 
toNm (9.43%) andNmWasthe most commonserogroup(52 cases= 5.38%).After introduction of conjugate vaccine A 
(MenAfriVac), the NmAserogroup almost disappeared both in asymptomatic carriers and in patients with cerebrospinal 
meningitis. However the presence of the NmW and NmXserogroups, which appear to have replaced serogroup A, is very 
worrying with regard to meningitis prevention and control in Burkina Faso. It appears necessary to strengthen surveillance 
and laboratory diagnosis of the different meningococcal serogroups circulating in Africa. 
Keywords: meningococcal meningitis, serogroups W and X, meningococcal carriage, MenAfriVac. 
 
PORTAGE DU MENINGOCOQUE ET MENINGITES CEREBROSPINALES APRES IMMUNISATION DE 
MASSE PAR LE MENAFRIVAC AU BURKINA FASO 
Ky-Ba1,*, A., Tranchot2, J., Sanou3, I., Christiansen4, P., Ouedraogo2, A. S., Ouattara5, K., Kienou5, M., Tamboura6, M., 
Kambiré6, D.,Ouédraogo-Traoré6, R., Sangaré5, L. 
RÉSUMÉ  
Objectifs: Evaluer l'impact du vaccin conjugué A, MenAfriVac, sur le portage asymptomatique du Neisseriameningitidis 
(Nm) et sur la méningite cérébrospinale dans trois districts sanitaires (Bogodogo, Kaya, et Dandé) du Burkina Faso. 
Matériel et Méthodes: Le portage asymptomatique de Nm a été évalué à travers une étude transversale avec plusieurs 
passages (round 1 à 10) avant et après l'introduction du vaccin conjugué contre le N. meningitidissérogroupe A (NmA), 
MenAfriVac. À chaque round, au moins 1.500 personnes ont été enrôlées dans chaque district pendant un mois. Les données 
sur les cas de méningites à méningocoque dans les trois districts sanitaires ont été recueillies à travers la surveillance 
épidémiologique des méningites du Burkina Faso. 
Résultats: Le Nm a été identifié dans 680 des 23 885 prélèvements de gorge avant la vaccination (2. 84%) et le NmY était le 
sérogroupe dominant (1,87%). Au cours de la même période (2009 et 2010), 891 cas suspects de méningites ont été notifiés 
dans les trois districts sanitaires, 42 cas étaient dus au Nm (4,71%) et NmX (3,70%) était le sérogroupe le plus fréquemment 
identifié. Après la vaccination, 1117 Nm (6,42%) ont été identifiés  des 27 245 prélèvements pharyngés, le NmX (4,42%) était 
le sérogroupe dominant. De 2011 à 2013, 965 cas suspects de méningites ont été enregistrés dans toutes les formations 
sanitaires des trois districts sanitaires étudiés; 91 étaient liés au Nm (9,43%), le sérogroupeNmW était le plus fréquent (52 
cas, 5,38%).  
Conclusion: Après l'introduction du vaccin conjugué A (MenAfriVac), le sérogroupe A (NmA) a presque disparu à la fois 
chez les porteurs asymptomatiques et chez les malades atteints de méningites cérébro-spinale. Toutefois, la présence des 
sérogroupesNmW et NmX, qui semblent avoir remplacé le sérogroupe A, est un très inquiétante en ce qui concerne la 
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prévention et le contrôle de la méningite au Burkina Faso. Il apparaît nécessaire de renforcer la surveillance et le diagnostic 
en laboratoire des différents sérogroupes de méningocoques qui circulent  
Mots clé: méningite cérébrospinale; serogroupes W et X, portage du méningocoque, MenAfriVac. 
INTRODUCTION 
Meningococcal meningitis is a serious public health 
problem, especially in the part of sub-Saharan 
Africa called the meningitis belt of Lapeyssonnie. 
This area stretches from Senegal to Ethiopia and has 
an estimated population about 500 million people. 
This belt has become a ramp that includes other 
African countries (1). Every year, an upsurge in 
cases of meningitis occurs during the dry season in 
countries located in this area, which thus have a 
high endemic background (1, 2, 3). 
According to the World Health Organization 
(WHO), there have been 700,000 cases of 
meningococcal meningitis globally over the last 15 
years,with an estimated lethality rate of more than 
10% and a considerable proportion of sequelae, 
sometimes reaching 20%(4).  
During epidemics, about 90% of cases are 
attributable to Neisseria meningitides serogroup A, 
W, X (3). Since records began, meningococcal 
serogroup A has been the dominant cause of 
epidemics of meningococcal meningitis in this 
region; however, NmW and NmX have also been 
responsible for epidemics (5, 6, 7, 8). 
Burkina Faso, a landlocked West African country 
with a population of roughly 18 million, is one of 
the few countries entirely located within the 
meningitis belt and has hyperendemic rates of 
meningitis (3, 9, 10). From 2003 to 2009, there were 
78,518 reported cases of meningococcal meningitis 
with 8,568 deaths (11%) in Burkina Faso. Among the 
fatal cases, 5.569 (65%) were caused by group A N. 
meningitides (11). 
From 2010 to 2012, NmX has been responsible for 
meningitis epidemics in Burkina Faso, causing 59% 
of the confirmed cases of meningococcal meningitis 
in this country in 2011(12).The lethality rates of 
meningitis caused by this serogroup were as high as 
those reported for NmA(12); children aged 1–9 
years being the most frequently affected age group 
(12). 
The mechanisms leading to the spread of infections 
linked to meningococcal infections and to epidemics 
of meningococcal meningitis remain unknown. The 
rate of asymptomatic carriage may reach 15% in 
Africa during epidemics (13, 14, 15). The 
environmental conditions present in the meningitis 
belt of sub-Saharan Africa during the dry season, 
particularly the high temperatures, very low 
humidity, and the Harmattan (dusty wind that 
blows from the Sahara), and respiratory co-
infections related to degradation of mucosal barriers 
defenses are considered to contribute to the increase 
in sensitivity to meningococcal disease (16,17,18, 
19). Several studies have shown the importance of 
the dynamics of asymptomatic carriage in 
individuals and communities and the effect of the 
season on colonization by meningococci (20, 21, 22, 
23). 
Over the past three decades, control of meningitis 
epidemics in the African meningitis belt has been 
confined to reactive vaccination with 
polysaccharide vaccine when the incidence in a 
given administrative area has reached a critical 
incidence (4). Implementing reactive vaccination 
with polysaccharide vaccine at the beginning of an 
epidemic has saved many lives; however, it does 
not decrease the frequency of outbreaks because 
polysaccharide vaccines confer protection for a 
limited time, especially in children, and have little 
or no impact on asymptomatic carriage (20). 
Conjugate vaccines, in which polysaccharidesare 
linked to a supportprotein, are likely to be more 
effective in preventing epidemics because they 
induce immunological memory and decrease 
pharyngeal carriage (21). 
As a prelude to the introduction of the conjugate 
vaccine A, Burkina Faso initiated a study of 
nasopharyngeal carriage of meningococcus in three 
health districts (Bogodogo, Dandé, and Kaya). After 
the introduction of immunization, other carriage 
studies have been conducted, mainly to evaluatethe 
impact of the vaccine on serogroup A and on the 
carriage of the other two main N. meningitides 
serogroups: X and W. 
In December 2010, the meningococcal A vaccine, 
MenAfriVac, was introduced in Burkina Faso 
through a mass vaccination program aimed at 
reducing the frequency of occurrence of cases and 
outbreaks related to serogroup A, which is the usual 
causative agent in the African cerebrospinal 
meningitis belt. Considering the results obtained 
elsewhere byadministering anti-meningococcal 
conjugate vaccines (24,25, 26), MenAfriVacwas 
expected to impact the rate of both carriage and the 
occurrence of meningitis due to NmA in Burkina. 
The aim of this study was to evaluate the impact of 
conjugate vaccine A, MenAfriVac, on the frequency 
of occurrence of clinical cases of cerebrospinal 
meningitides and NmA carriage, and possibly cases 
associated with other common serogroups in 
Burkina Faso. 
MATERIALS AND METHODS 
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Ethical Considerations                                                       
This study was approved by the Ethics Committees 
of Health Research in Burkina Faso, the Regional 
Committee for Research insouthern Norway, and 
the Commission of Internal Revision of the Centers 
for Disease Control in Atlanta, GA, USA.Written 
informed consent was obtained from all study 
participants or their parents or guardians. 
Study Sites                                                                                  
The study was conducted in three health districts of 
Burkina Faso (Bogodogo, Kaya, and Dandé). 
Villages or sectors in each district were chosen 
randomly. In BogodogoDistrict, an urban district 
located in the capital of Burkina Faso, 
oropharyngeal samples and cerebrospinal fluid 
wereprocessed by the laboratory of Charles De 
Gaulle pediatric hospital. In Kaya District, which is 
a rural district located in north-eastern Burkina 
Faso, samples were sent to and processed by the 
laboratory of the Regional Hospital of Kaya (CHR) 
and the bacteriology laboratory of the university 
teaching hospital of Yalgado Ouedraogo. Finally, in 
the rural district of Dandé, which is located in the 
western part of the country, the Bacteriology 
Laboratory of the university teaching Hospital of 
Bobo Dioulasso, Souro Sanou Hospital, was in 
charge of bacteriological analysis of samples. 
Type and period of the study  
This descriptive cross-sectionalstudy was 
performed foranalytical purposes and 
comprisedfive separate rounds 3 monthsbefore and 
after vaccination. The study was conducted from 
January 2009 to November 2011.During this period, 
specimens were collected to obtain data on 
asymptomatic carriage of N. meningitidis. However, 
data related to cerebrospinal meningitis cases was 
collected continuously between 2009 and2013 in the 
three health districts studied. 
Sampling for meningococcal carriage 
A sample representing persons aged 1 to 29 years 
was obtained by cluster sampling at several levels 
as follows: 
Eight villages were selected randomly in each of the 
two rural districts studied (Dandé and Kaya). For 
each campaign, 42 concessions per village were 
selected by simple random sampling from maps 
showing the Global Positioning System (GPS) 
coordinates of all concessions in the selected 
villages, these maps having been prepared before 
the start of the study. All persons in the target 
group who lived in one of the randomly selected 
concessionswere invited to participate in the study. 
 
In the urban district studied (Bogodogo), all 
residential blocks were identified on a geographical 
map of the district. Sixteen blocks per campaign 
were selected by simple random sampling and 
mapped with GPS coordinates. During each 
campaign, all households in the selected blocks 
were visited and eligible subjects invited to 
participate in the study. 
 
Sampling for cases of cerebrospinal meningitis  
The sample of cases of cerebrospinal meningitis 
comprised all cases registered in the Ministry of 
Health database (National Epidemiological 
Surveillance System) during the period of the 
study.The cases of cerebrospinal meningitisin the 
three health districts studied (Bogodogo, Dandé, 
and Kaya) were selected according to the WHO 
definition of acute bacterial meningitis, which 




Data collection for meningococcal carriage  
The residents of the study sites were first informed 
of the project by local health workers and 
community leaders. Each randomly selected 
household was visited by the study staff and 
questionnaires administered to all target family 
members after they had signed individual 
writteninformed consent forms. The consent of a 
parent or guardian was obtained for children aged 
less than 18 years. Oropharyngeal specimens were 
obtained by swabbing the posterior wall of the 
pharynx with a sterile cotton swab, these samples 
being collected by technicians who had previously 
been trained to take such swabs.Each participant 
received a paper bracelet with a bar code 
corresponding to a unique identification number 
linked to the questionnaire. 
 
Data collectionfor cases of meningococcal 
meningitis 
Data was collected on an especially designed form 
for each case. The primary tools for collecting these 
data were clinical records, recordsofnotification of 
cases, the documents that accompanied the samples, 




Rate of carriage of meningococcus in the selected 
three health districts of Burkina Faso before the 
introduction of meningococcal A conjugate vaccine 
MenAfriVac 
 
The overall carrier rate of serogroup Nm before 
vaccination was 2.84% (680/23885) (Table I). In the 
Bogodogo health district, the overall carriage rate 
was 1.08% (93/8596) and the carriage rates of 
NmA0.11%, of NmX0.32%, of NmY0.51%, and of 
NmW0.12%. In the Dandé health district, the overall 
carriage rate was 3.14% (270/8582) and the carriage 
rates of NmA0.18%, ofNmX0.27%, of NmY2.49%, 
and of NmW 0.20%. Finally, in the Kaya health 
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district, the overall carriage rate was 4.72% 
(317/6707) and the carriage rates of NmA 0.83%, of 
NmX 0.79%, of NmY 2.81%, and of NmW 0.28%. 
 
Notably, the prevalence of NmY (65.7%) prior to 
vaccination was 4-fold that ofNmX (15.3%), 5-fold 
that ofNmA (12.1%) and more than 9-fold greater 
than that ofNmW (6.9%)(Table II). 
Types of meningococcus responsible for 
cerebrospinal meningitis in the three studied 
health districts before introduction of the anti-
meningococcal A conjugate vaccine  
From 2009 to 2010 (before the vaccination 
campaign), 891 cases of suspected bacterial 
meningitis were reported in the three studied health 
districts; 97 of these cases (10.88%) having been 
confirmed by laboratory analysis. Among the 92 
confirmed cases, 42 (43.2%) were caused byN. 
meningitidis, 51 (52.57%) by Streptococcus pneumonia 
and four (4.12%) by Haemophilus influenzae. The 
distribution of serogroups of N. meningitidis was as 
follows: five cases (5.15%) of NmA, 33 (34.02%) of 
NmX, and four (4.12%) of NmW. All the NmA 
strains isolated were from theDandé district, 
whereas NmX was isolated in 16 cases (16.49%) in 
Kaya, nine (9.27%) in Bogodogo, and eight (8.24%) 
in Dandé health districts. Finally, NmW was 
isolated in two cases in Kaya (2.06%) and two in 
Dandé (2.06%). 










































































 Total 2 8582 16 23 214 17 
























 Total 3 6707 56 53 189 19 
 
TABLE II: MENINGOCOCCAL CARRIAGE RATE IN THE THREE HEALTH DISTRICTS AFTER VACCINATION 
Sites Rounds Number of 
participants 
Sérogroup A Sérogroup 
X 
















































































































Meningococcal carriage rate in the three studied 
health districts of Burkina Faso after vaccination 
with MenAfriVac  
The overall carriage rate Nm after vaccination was 
6.42% (1749/27245)(Table II). In the health district of  
Bogodogo, the overall carriage rate was 1.10% 
(95/8568), comprising one case (0.01%) of NmA, 36 
(0.42%) of NmX, eight (0.09%) of NmY, and 50 
(0.58%) of NmW.In the health district of Dandé, the 
global carriage rate was 533/8561 (6.2%), 
comprising52 (0.60%) of NmX, 137 (1.60%) of NmY, 
and 344 (4.01%) of NmW. No NmA serogroup was 
isolated in this district. In the health district of Kaya, 
the carriage rate was 11.08% (1121/10 116), 
comprising1029 (10.17%) of NmX, 53 (0.52%) of 
NmY, and 39 (0.38%) NmW. No NmAserogroup 
was isolated in this district. 
 
After immunization, the prevalence of NmX was 
almost three-fold (63.9%) that of NmW (24.8%) and 
five-fold that ofNmY (11.3%). However, NmA was 
isolated in only 0.1% of participants. 
 
Meningococcus responsible for cerebrospinal 
meningitidis in the three studied health districts 
after vaccination with MenAfriVac 
The MenAfriVac vaccine was introduced in Burkina 
Faso December 2010; thus, the period from 2011 to 
2013 was considered the post-vaccination period. 
During this period, 965 suspected cases of 
meningitis were reported in the three studied health 
districts, 179 (18.54%) of these cases being 
laboratory-confirmed. Among the confirmed cases, 
91 (50.83%) were caused byN. meningitidis, 83 
(46.36%) by S. pneumoniae, and five (2.79%) by H. 
influenzae. The distribution of N. meningitides 
serogroups was as follows: 58 cases (32.40%) of 
NmX, 52 (29.05%) of NmW, one (0.55%) of NmY, 
and none of NmA (Table III). 
 
TABLE III: SUMMARY TABLE OF THE MENINGITIS DATA OF 2009, 2010, 2011, 2012 AND 2013 IN THE HEALTH DISTRICTS OF 
BOGODOGO, DANDÉ AND KAYA 
Districts   Year 
  2009 2010 2011 2012 2013 
Bogodogo Hib 2 1 1 0 0 
 Negative 99 120 105 55 39 
 NmA 0 0 0 0 0 
 NmW 0 0 4 7 5 
 NmX 0 9 1 2 0 
 NmY 0 0 1 0 0 
 Sp 10 17 16 1 4 
 Total 111  147 128 65 39 
Dandé Hib 0 0 1 0 0 
 Negative 15 140 121 163 29 
 NmA 0 5 0 0 0 
 NmW 0 2 2 15 10 
 NmX 0 8 0 3 0 
 NmY 0 0 0 0 0 
 Sp 3 5 9 1 12 
 Total 18 160 133 182 41 
Kaya Hib 1 0 1 1 1 
 Negative 137 289 44 102 165 
 NmA 0 0 0 0 0 
 NmW 0 2 3 5 1 
 NmX 6 10 15 12 5 
 NmY 0 0 0 0 0 
 Sp 7 9 16 11 13 
 Total 145 310 61 131 185 
 
As to sites, the single NmY strain was from 
Bogodogo health district. NmX and NmY strains 
were identified in all three study sites.In Kaya, 32 
cases (17.87%) of NmX and nine (5.02%) of NmW 
were identified; in the Dandé district, 27 cases 
(29.67%) of NmWandthree (3.29%) of NmX, and in 
the Bogodogo district, 16 cases (17.58%) of NmW 
and three (3.29%) of NmX. 
 
DISCUSSION                                                         
Cerebrospinal meningitis is a major public health 
problem in countries of the meningitidis belt such as 
Burkina Faso. With the aim of reducing the negative 
impact of this disease, there havebeen vaccination 
campaigns in Burkina Faso and many other African 
countries that are subject to outbreaks of this 
disease.  
 
TheMenAfriVac vaccine wasspecifically developed 
to targettheNmAserogroup. Prior to the vaccination 
campaign, the prevalence of asymptomatic carriage 
of this serogroup was 0.11% in the Bogodogo 
district, 0.18% in the Dandé district, and 0.83% in 
the Kaya district. Post-vaccination, a single NmA 
carrier was identified intheBogodogo district; this 
carrier had not received the MenAfriVac vaccine. 
Thus, this study showed that NmA carriage had 
almost total disappeared from the three study sites, 
confirming that the conjugate vaccine MenAfriVac 
greatly reduces the prevalence of NmA carriage (23, 
27, 28, 29, 30). A study conducted in Brazil in 2010 
also showed that the conjugate vaccine reduces the 
prevalence of rhinopharyngeal colonization by Nm 
(31). Our findings are similar to those of a study 
conducted in Chad from 2009 to 2012, which also 
showed that the MenAfriVac vaccine led to a 
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reduction in the prevalence of rhinopharyngeal 
colonization byNmA (30). 
 
Before the 2009–2010 MenAfriVacvaccination 
campaign, the NmAserogroup was only isolated 
from CSF of patients with cerebrospinal meningitis 
in the Dandé district (5.15% of laboratory-confirmed 
cases). Despite the presence of asymptomatic 
carriage of NmA in the Bogodogo (0.11%) and Kaya 
districts (0.83%), NmAwas not isolated from the 
CSF of any patients from these two health districts 
before the vaccination campaign. This may be 
attributable to the effect of the reactive mass 
vaccination (polysaccharide vaccine A/C and 
A/W/Y/C) performed in Kaya in 2007 and 2008 
and in Bogodogo in 2008 (9). Of note, people in the 
Dandédistrict had not received vaccination in 2009 
with the polysaccharide vaccine, which provides 
short-lived immunity (2–3 years) against the 
serogroups that it contains and is less active in 
children aged less than 2 years (32). 
 
However, post-vaccination, NmA was not isolated 
from the CSF of any patients with cerebrospinal 
meningitis in any if the studydistricts. This 
disappearance of NmA may be associated with the 
effect of the MenAfriVac conjugate vaccine on this 
serogroup. This finding is similar to those of several 
other studies (33, 34). 
 
Of note, we found an increase in prevalence of NmX 
carriage post-vaccination in the Bogodogo and Kaya 
districts, from 0.32% to 0.42% and from 0.79% to 
10.17%, respectively. In contrast with patients with 
meningitis in Bogodogo, the prevalence of NmXwas 
higher in the CSF of patients with meningitis in the 
Kaya district post-vaccination, doubling from 16 to 
32 cases compared with the pre-vaccination era. The 
particularly high prevalence of asymptomatic 
carriers of NmX in theBogodogo and Kaya districts 
and of laboratory-proven NmX cerebrospinal 
meningitis in theKaya health district could be 
related to the close proximity of these districts to 
Niger, where outbreaks caused by this 
serogrouphaveoccurred since 2006 (7, 35, 36). 
 
Also of note, the post-vaccination NmW carriage 
rate in the Dandé health district was 20-fold that 
before introduction of the vaccine (0.20% vs. 4.01%). 
Similarly, the post-vaccination prevalence of 
laboratory-confirmed NmW meningitis in this 
district was 9-foldthat found in the pre-vaccination 
era.This very significant presence of the NmW 
serogroup in the Dandé district post-vaccination is 
likely related to the proximity of this city to Mali,in 
which cases of laboratory-confirmed NmW 
meningitis were reported in 2007 and 2009 (34, 37). 
A post-vaccination increase in the prevalence of 
asymptomatic carriers of NmWwas also seen in the 
health district of Bogodogo, the rate there increased 
from 0.12% to 0.58%. Also, whereas this serogroup 
had not been isolated from patients with meningitis 
in this district pre-vaccination, post-vaccination 
there were 16 such cases (17.58%). Of note, the 
capital of Burkina Faso (Ouagadougou), in which 
theBogodogo district is located, is a crossroads 
through which many people continuously move 
into the country for diverse reasons. The significant 
presence of the NmW serogroup in this town could 
be attributable to thisinflux of people, including 
some from areas to the west thathave borders 
withMali. 
 
Studies by Paul and colleagues have shown that the 
NmW observed in Burkina Faso post-vaccination 
belong to the NmW clone ST-11, which hadlast been 
seen in the country in 2006 but reappeared after the 
MenAfriVac nationwide mass vaccination campaign 
(38). This clone has been identified both in carriers 
of NmW non-invasive strains and in patients with 
meningitis (23, 34,39). Thus far, the ability of NmW 
to cause large epidemics has been associated with 
the hyper-virulent ST-11 clone (34, 40,41, 42). In our 
study, we identified persistence of the NmW 
serogroup in 2013 in patients in the Bogodogo and 
Dandé districts. This may imply that a new strain of 
hyper-virulent NmW emerged after the mass 
vaccination with MenAfriVac, which resulted in the 
disappearance of NmA carriers and patients with 
laboratory-confirmed NmA meningitis in the three 
studied health districts. 
 
In general, we believe it is important to note that the 
unusual emergence of NmX and NmW serogroups 
post-vaccination was associated with the virtual 
absence of NmA. This finding is particularly 
relevant in light ofthe observed increase in overall 
prevalence of meningococcus after vaccination with 
MenAfriVac conjugate vaccine in the sites of our 
study among asymptomatic carriers (from 2.84% to 
6.42%) and patients with meningitis (from 43.2% to 
50.83%). Of note, there was also an increase in the 
global meningococcal carriage rate in the 
threestudied districts. Indeed, in the Bogodogo 
district it increased from 1.08% to 1.10%, in 
Dandéfrom 3.14% to 6.2%, and in Kaya from 4.72% 
to 11.08%. This increase in prevalence of 
asymptomatic carriers of meningococcuspost-
vaccination was linked with a very low rate of 
carriage of NmA. Paul et al. reported similar 
findings (43). 
 
In contrast with these two serogroups, we identified 
a significant decrease in the rate of carriage of NmY 
within the three studied districts post-vaccination. 
The prevalence of this serogroup dropped from 0.51 
% to 0.09% in Bogodogo, from 2.49% to 1.60% in 
Dandé, and from 2.81% to 0.52% in Kaya. This 
reduction may reflect the effects of group immunity, 
including immunity against NmA. Despite the very 
high prevalence of carriage of this serogroup in all 
the health districts, analysis of CSF from patients 
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with meningitis in all three studied districts post-
vaccination revealed a single patient from whom 
NmYwas isolated, this patient being in the 
Bogodogo health district. Serogroup Y 
meningococcal meningitis does not appear to be 




In this study, we identified the disappearance of 
both NmA carriage andserogroup A meningococcal 
meningitis since the introduction in Burkina Faso of 
the MenAfriVac anti meningococcal A conjugate 
vaccine in December 2010. Despite the introduction 
of this vaccine, Burkina Faso remains vulnerable to 
outbreaks related to serogroup X, for which no 
vaccine is currently available, and to re-emergence 
of serogroup W, because the prevalence of these two 
serogroups both in asymptomatic carriers and in 
patients with meningitis has increased post-
vaccination in the three studied health districts. It is 
therefore essential to review strategies against acute 
bacterial meningitis. Strengthening surveillance is 
essential to monitoring these changes, 
detectingepidemics in a timely manner and 
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